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Abstract
Introduction: Complement activation is involved in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)
and atypical hemolytic uremic syndrome (aHUS). Autoantibodies to complement inhibitor factor H (FH), particularly
in association with deletions of the gene coding for FH-related protein 1 (CFHR1), are associated with aHUS.
Methods: Autoantibodies against FH, factor I (FI) and C4b-binding protein (C4BP) were measured by ELISA, while
CFHR1 homozygous deletion was determined with Western blotting of sera. Epitopes for FH autoantibodies were
mapped using recombinant fragments of FH.
Results: FH autoantibodies were detected in SLE (6.7%, n = 60, RA patients (16.5%, n = 97 in the Swedish cohort
and 9.2%, n = 217 in the Dutch cohort) and thrombosis patients positive for the lupus anticoagulants (LA+) test
(9.4%, n = 64) compared with aHUS patients (11.7%, n = 103). In the control groups (n = 354), an average of 4% of
individuals were positive for FH autoantibodies. The frequencies observed in both RA cohorts and LA+ patients
were statistically significantly higher than in controls. We also found that an average of 15.2% of the FH-
autoantibody positive individuals in all studied disease groups had homozygous deficiency of CFHR1 compared
with 3.8% of the FH autoantibody negative patients. The levels of FH autoantibodies varied in individual patients
over time. FH autoantibodies found in LA+, SLE and RA were directed against several epitopes across FH in
contrast to those found in aHUS, which bound mainly to the C-terminus. Autoantibodies against FI and C4BP were
detected in some patients and controls but they were not associated with any of the diseases analyzed in this
study.
Conclusions: Autoantibodies against FH are not specific for aHUS but are present at a significant frequency in
rheumatic diseases where they could be involved in pathophysiological mechanisms.
Introduction
Complement is a central innate defense system that pro-
motes the inflammatory response and destroys microbes.
In addition, complement is also involved in the instruc-
tion of the adaptive immune response and the clearance
of dead cells and misfolded proteins [1,2]. Complement
consists of plasma- and membrane-associated proteins
and can be activated through the classical, the lectin and
the alternative pathways [3].
Complement is an aggressive, self-amplifying cascade
that needs to be tightly regulated by both soluble and
membrane-bound inhibitors to prevent damage of host
tissues. The soluble inhibitor C4b-binding protein
(C4BP) has a central role in regulating the classical and
the lectin pathways [4], while Factor H (FH) and its splice
variant FH-like protein 1 (FHL-1) corresponding to com-
plement control protein (CCP) domains 1-7 of FH are
the most important soluble inhibitors of the alternative
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pathway [5]. Factor I (FI) is a serine protease that inhibits
all complement pathways but works only in the presence
of its specific cofactors, such as FH and C4BP [6,7].
Defective activation of complement as well as insufficient
inhibition are associated with pathological processes in a
number of autoimmune and inflammatory diseases [8]
including rheumatoid arthritis (RA) [9], systemic lupus
erythematosus (SLE) [10-12], anti-phospholipid syn-
drome (APS) [13] and atypical hemolytic uremic syn-
drome (aHUS) [14]. In addition to genetic variants,
autoantibodies also have been reported to have an impact
on the function of complement factors and on diseases
[15]. It is now well established that the presence of auto-
antibodies against complement FH is associated with
aHUS [16-20] and it was also reported that the deletion
of complement FH-related proteins 1 and 3 (CFHR1/
CFHR3) in aHUS patients are associated with the disease
[21,22]. This autoimmune subtype of aHUS with unique
characteristics was recently termed DEAP-HUS (the
Deficiency of CFHR plasma proteins and Autoantibody
Positive form of HUS) [23]. Interestingly most of the
FH- autoantibodies in aHUS are directed against the C-
terminal recognition region of FH [17].
In this study we have examined the frequency of FH-
autoantibodies in groups of patients with different dis-
eases, such as RA, SLE and thrombosis patients positive
for lupus anticoagulants (LA+) test and compared these
with an aHUS cohort. We have also investigated if the
presence of those antibodies is associated with deficiency




Plasma samples from consecutive unselected patients with
RA (n = 314) were collected in three centers: at the
Department of Rheumatology, Lund University Hospital,
Lund, Sweden (n = 30); the Department of Rheumatology
and Inflammation Research, Gothenburg, Sweden (n = 67)
and at the Department of Rheumatology, Leiden Univer-
sity Medical Center, Leiden, The Netherlands (n = 217).
The RA samples from Sweden (Lund and Gothenburg)
were analyzed as one cohort. All patients fulfilled the
American College of Rheumatology criteria for RA [24].
Four of the FH-autoantibody positive patients from the
Lund cohort were then chosen and the FH-autoantibodies
were measured in several samples collected from these
four patients, mainly after the first positive, analyzed
sample.
Plasma samples from patients with SLE were collected
at the Department of Rheumatology, Lund University
Hospital, Sweden. From each patient (n = 30) two sam-
ples were available, selected from time points with lower
(median = 12, range = 12) and higher disease activity
(median = 32, range = 28) as measured by SLE disease
activity index (SLEDAI). All SLE patients fulfilled four or
more American College of Rheumatology classification
criteria for SLE [25,26].
Plasma samples from thrombosis patients positive for
lupus anticoagulants (LA; screen test) using dilute Rus-
sels Viper Venom [27] (dRVVT) (Siemens; Marburg,
Germany) and thus with highly likely diagnosis of APS
(n = 64) were collected at the Department of Clinical
Chemistry, Skåne University Hospital Malmö, Sweden.
Since the LA test was performed only on one occasion
before the samples were de-identified, these patients do
not fulfill Sydney criteria for APS diagnosis [28]. aHUS
patients (n = 103) from the Jena registry [22] were
recruited based on the initial clinical diagnosis aHUS.
Controls used were collected from unrelated healthy
volunteers from Germany (n = 20) and The Netherlands
(n = 161) and matched in average age and sex. The total
number of 173 Swedish controls was divided into groups
exactly matching in age and sex to each disease group
(SLE, RA, LA+) for the analysis of FH autoantibodies.
These controls were matched in average age and sex for
the analysis of FI and C4BP autoantibodies. The study
was approved by the regional ethics committees of Jena,
Lund, Leiden and Gothenburg Universities and all parti-
cipants have given informed consent.
Determination of FH-, FI- and C4BP-autoantibodies levels
and identification of autoantibody positive patients
Plasma samples from patients with RA, SLE, LA+, aHUS
and controls were screened for the presence of FH-, FI-
and C4BP-autoantibodies using enzyme-linked immuno-
sorbent assay (ELISA). Microtiter plates (Maxisorp; Nunc,
Roskilde, Denmark) were coated overnight with purified
FH, FI and C4BP diluted to 1 μg/ml in 75 mM sodium-
carbonate buffer, pH 9.6. FH was purified from plasma
[29] and passed through protein A-Sepharose HiTRAP,
(GE Healthcare, Uppsala, Sweden) to remove any contami-
nating human immunoglobulins. C4BP and FI were
expressed recombinantly in human embryonic kidney 293
(HEK 293) cells and purified by affinity chromatography
as described [30,31]. The plates were blocked with PBS/1%
BSA for 1 h at 37°C after which plasma samples diluted
1:50 times in PBS/1% BSA/Tween 0.05% were added to
the plates. After 1 h incubation at 37°C the plates were
washed four times with washing buffer (50 mM Tris-HCl,
150 mM NaCl, 2 mM CaCl2 and 0.1% Tween 20; pH 8.0).
FH-, FI- and C4BP-autoantibodies were detected with
rabbit anti-human IgG Abs (DakoCytomation, Glostrup,
Denmark) followed by swine anti-rabbit Abs conjugated
with horseradish peroxidise (HRP) (DakoCytomation).
The plates were developed with o-phenylenediamine
(OPD) substrate (DakoCytomation) and the absorbance
was measured at 490 nm (Varian 50 MPR Microplate
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Reader). Concentrations of FH-, FI- and C4BP-autoantibo-
dies were calculated relative to a standard set at 100 AU/
mL. Polyclonal goat antibodies against human FH (Quidel,
San Diego, CA, USA) and rabbit antibodies against human
FI (PK9205, generated in house) and human C4BP
(PK9008, generated in house) were used as standards at
two-fold dilution series starting from 1:8,000, 1:200 and
1:2,000, respectively.
The samples with levels above the mean plus two stan-
dard deviations (SD) of those in the matched control
group were considered positive and are indicated by
dotted lines in each panel of Figure 1. The cut-offs were
calculated separately for each country control group and
for each control group matched to a Swedish disease
group. The cut-offs for FH-autoantibodies were >98.7 AU/
mL (RA, Sweden), >90.5 (SLE Sweden), >102.3 (LA+,
Sweden), >113.2 AU/mL (RA, The Netherlands) and >89.2
AU/mL (aHUS, Germany). The cut-offs for FI-autoantibo-
dies and C4BP-autoantibodies were >203.6 AU/mL and
>407.2 AU/mL, respectively, based on the Swedish control
group consisting of 39 healthy individuals.
To analyze the specificity of the assay, 8 μg/well of puri-
fied FH, FI, C4BP were added to several plasma samples
with high autoantibody titers diluted 1:50. The samples
A
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Figure 1 Identification of FH, FI and C4BP autoantibody positive patients. Plasma samples of LA+, SLE, RA, aHUS patients and healthy
controls were analyzed for binding of IgG autoantibodies on immobilized purified FH (A-D), recombinant FI (E) or recombinant C4BP (F) using
ELISA. FH-autoantibody titers for individual SLE patients characterized by presence of FH-autoantibodies divided according to SLEDAI score
indicating low and high disease activity for the same patients are shown in Figure 1D. Values obtained for the same patient are connected by
lines. The samples with levels above the mean plus 2 SD of those in the matched control group were considered positive. The dotted lines
represent cut-offs calculated separately for each control group. Statistical significance of differences between autoantibody titers in diseases
groups compared with controls was calculated using a Kruskal-Wallis test or Mann-Whitney test. P-values lower than 0.05 were considered
statistically significant. ** P < 0.01; *** P < 0.001, ns not significant.
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were then pre-incubated at RT for 2 h before performing
the analysis. We believe that the assay is not affected by
the presence of rheumatoid factor because FH was directly
immobilized on plates. In support, we found no associa-
tion between positivity for rheumatoid factor and FH
autoantibodies (not shown). An additional specificity con-
trol was performed by incubating polyvinylidene difluoride
(PVDF) membrane fragment containing excised band cor-
responding to FH with serum of a patient positive for FH
autoantibodies. The bound antibodies were eluted with
0.1 M glycin, 0.3 M NaCl pH 2.7, neutralized with Tris
buffer and incubated with another PVDF membrane con-
taining separated purified FH, pre-albumin and lysate of
HEK 293 cells spiked with purified FH. Bound antibodies
were then visualized by sequential incubation of the mem-
brane with rabbit anti-human IgGs and goat anti-rabbit
HRP conjugated antibodies, followed by development with
a colorimetric substrate. The FH autoantibody assay has
now been reproducibly established by several independent
research groups [17,19,32].
Determination of binding site for FH autoantibodies
using FH fragments
Several serum samples positive for FH autoantibodies were
chosen from each patient group to localize the binding
domains. These were incubated with immobilized BSA,
FH, FHL-1 and recombinant FH fragments expressed as
described previously in a baculovirus system and com-
posed of CCPs 8 to 20, CCPs 15 to 20 and CCPs 19 to
20 [17]. The fragments were immobilized at equivalent
molar concentrations corresponding to 1 μg/ml FH and
antibody binding was determined as described above.
Western blot analysis
Plasma samples from 64 LA+, 60 SLE, 314 RA, 101 aHUS
patients and 354 controls were investigated for the pre-
sence of CFHR1. Plasma samples diluted 1:100 were
separated under non-reducing conditions using 12%
SDS-PAGE. The proteins were transferred onto PVDF
membrane, blocked with quenching solution (washing
buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.1% (v/v)
Tween 20, pH 7.5 with 0.3% fish gelatin, Norland Pro-
ducts, Cranbury, NJ, USA) and incubated with mouse
monoclonal anti-FH (C18/3; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) that identifies the conserved
C-terminus of FH (150 kDa) and the two differentially
glycosylated forms of CFHR1a and CFHR1b (37 and
42 kDa). Bound antibodies were detected with a polyclo-
nal anti-mouse IgG antibody conjugated with HRP
(DakoCytomation). Finally, the blots were developed
using 3,3’-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich, St Louis, MO, USA) colorimetric substrate sys-
tem as described before [33].
We have confirmed the capacity of the Western blot
technique to reliably identify CFHR1 deletion by compar-
ing 70 RA samples tested by both Western blot and genetic
analysis using Mutiplex Ligation-dependent Probe Amplifi-
cation (MLPA) (MRC-Holland, Amsterdam, the Nether-
lands) following the instructions from the manufacturer.
Statistical analysis
Differences between the patients and controls were eval-
uated using Mann-Whitney test. P-values lower than
0.05 were considered statistically significant.
Results
FH autoantibodies are present in sera of patients with
rheumatic diseases
Autoantibodies against FH (Figure 1A-D), FI (Figure 1E)
and C4BP (Figure 1F) were analyzed in samples of LA+,
SLE, RA and aHUS patients as well as in healthy controls
using ELISA. The samples with levels above the mean plus
2 SD of those in the country as well as disease specific
control groups were considered positive, as indicated by
dotted lines in each panel of Figure 1.
In the Swedish control groups matched individually to
RA, SLE and LA+ patients, only two (2.1%) healthy indi-
viduals were positive for FH-autoantibodies in the con-
trol group matched to RA patients, three (5%) in the
group matched to SLE patients and four (6.3%) matched
to LA+ patients. In the control groups of 161 (The
Netherlands) and 20 (Germany) healthy individuals,
5 (3.1%) and 1 (5%) FH-autoantibody positive samples
were detected. In the cohorts of LA+, SLE, RA and
aHUS patients, we identified several patients positive for
FH-autoantibodies (Figure 1A-D). The cohort of aHUS
patients was used as a positive control and, indeed, we
observed a statistically significant (P < 0.01) increase in
frequency of FH-autoantibody positive individuals in
aHUS as compared to the controls. The previously
reported frequency of FH-autoantibodies in the German
cohort of 147 aHUS patients was 11% (16/147) [17,18]
compared with 9% (13/142) in the Newcastle cohort
[19], which corresponds well with our results (11.7%)
for aHUS patients.
Interestingly, also in the Swedish RA patients, a signifi-
cantly increased (P < 0.01) frequency of FH-autoantibody
positive patients was observed as compared to matched
healthy controls (Figure 1A). Independent international
replication was sought using a cohort of Dutch RA
patients and their controls. Also, here an increased
frequency of FH-autoantibody positive patients was
observed (P < 0.001; Figure 1B). The frequencies
observed were reaching up to 16.5% in the Swedish
cohort and 9.2% in the Dutch cohort (Figure 1A and
Table 1).
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Also in the group of LA+ patients, a positive signal for
FH-autoantibodies was observed for 9.4% patients,
which was higher compared to healthy controls (P <
0.01). Only 6.7% of the SLE plasma samples analyzed
were positive for the presence of FH-autoantibodies,
which was not significantly different from healthy con-
trols (Figure 1A). FH-autoantibodies could only be
detected in SLE-patients at the time point with higher
disease activity (Figure 1D). The mean titer of FH-auto-
antibodies for all FH autoantibodies positive patients
from the groups with rheumatic diseases was 161.2 AU/
mL compared with 363.6 AU/mL for aHUS patients.
Furthermore, we did not observe a statistically signifi-
cant correlation between FH-autoantibody titers and age
(ranging from 16 to 94 years) or sex when analyzing all
controls and patients together or separately.
In order to test if the studied diseases are character-
ized by autoantibodies against several complement inhi-
bitors or only against FH, we also analyzed autoantibody
reactivity against complement inhibitors C4BP and FI.
The results from the ELISA measurement of FI- and
C4BP-autoantibodies in cohorts of LA+, SLE, RA (Swed-
ish cohort) showed that there is no obvious association
between these autoantibodies and any of the rheumatic
conditions investigated (Figure 1E, F). Likewise, we did
not find an association between FI- and C4BP-autoanti-
bodies and aHUS (not shown).
FH autoantibody status varies during the course of
disease
Four FH-autoantibody positive RA patients, from the
Lund cohort, were analyzed for variation of FH-autoanti-
bodies positivity varies during the disease course. The dis-
ease duration for the chosen patients varied between 0.5
to 35 years and also the time interval between the first and
last collected sample ranged from 3 months to 22 years.
Two patients had no detectable FH-autoantibodies in all
samples drawn after the initial, FH-autoantibody positive
sample. For the third patient, the first FH-autoantibody
negative sample was followed by a positive one and then
seven negative ones, whereas the last patient had FH-auto-
antibodies in all three samples tested. Together with the
observed difference for SLE patients with high and low
SLEDAI index, these results show that the FH-autoanti-
body status is not constant during the disease’s progress.
Determination of binding site for FH-autoantibodies
using FH fragments
In order to determine the regions of FH that are recog-
nized by autoantibodies, we analyzed by ELISA a few
Table 1 Frequency of FH-autoantibodies and CFHR1 deficiency in patients compared to healthy controls.






Odds Ratio for anti-FH positivity in
CFHR1 deficiency




OR 95% CI P-value
LA+
Sweden
64 9.4 6 5 (83.3) 58 1 (1.7) 285 15.4 to 5,280 <0.0001
Controls
Sweden
64 6.3 4 1 (25.0) 60 1 (1.7) 20 1.0 to 397 1.12
SLE
Low SLEDAI, Sweden
30 0.0 0 0 (0.0) 30 1 (3.3) n.a1
Controls
Sweden
30 0.0 0 0 (0.0) 30 0 (0.0) n.a.
SLE
High SLEDAI, Sweden
30 13.3 4 0 (0.0) 26 1 (3.8) 2.0 0.066 to 54.1 1
Controls
Sweden
30 10.0 3 0 (0.0) 27 1 (3.7) 6.3 0.17 to 231 1
RA
Sweden
97 16.5 16 2 (12.5) 81 5 (6.2) 2.0 0.38 to12.3 0.3
Controls
Sweden
97 2.1 2 0(0.0) 95 1(1.1) 12.3 0.44 to 384 1
RA
The Netherlands
217 9.2 20 0 (0.0) 197 7 (3.6) n.a.
Controls
The Netherlands
161 3.1 5 0 (0.0) 156 13 (8.3) n.a.
aHUS
Germany
103 11.7 12 3 (25.0) 91 4 (4.4) 6.45 1.25 to 33.05 0.04
Controls
Germany
20 5.0 1 0 (0.0) 19 0 (0.0) n.a.
1n.a., not applicable due to 0% frequency
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positive samples from each disease group and several
fragments of FH and FHL-1. We confirmed that all
selected samples contained autoantibodies reacting with
intact FH with the highest levels found in the three
selected aHUS patients and one LA+ patient (Figure 2B).
We found that FH-autoantibodies present in aHUS/
DEAP-HUS patients bound mainly to the C-terminus of
FH as previously reported [17], since we detected the
strongest signals of the three serum samples of aHUS
patients for intact FH, CCPs 15 to 20 and CCPs 19 to 20
but very low level of interaction with FHL-1, which con-
tains only CCP1 to 7 (Figure 2). To the contrary, samples
from RA, LA+ and SLE reacted in a similar manner with
all used fragments of FH, including FHL-1. This indi-
cated that FH-autoantibodies found in rheumatic diseases
lack specificity for the C-terminus of FH as found in
DEAP-HUS.
CFHR1 deficiency in patients with rheumatic diseases and
aHUS
Since in aHUS an association was reported between the
presence of FH-autoantibodies and homozygous deletions
of the gene encoding CFHR1 and CFHR3 [22], we now
also analyzed whether there is such an association in rheu-
matic diseases. Previously, a good correlation was shown
between the genetic deficiency of CFHR1 and the lack of
CFHR1 protein detected by Western blotting in samples of
aHUS patients [34] and thus we used the latter analysis to
determine the frequency of CFHR1 deficiency. We con-
firmed the CFHR1 deficiency on Western blot with
CFHR1 genetic deficiency in 70 RA patients using MLPA
and observed a 100% match between the two techniques.
The Western blot shows both FH (approximately 150 kDa)
and the two glycosylated forms of CFHR1a and CFHR1b
(approximately 38 and 43 kDa). A typical Western blot
analysis showing examples of CFHR1 positive and deficient
patients is shown together with controls (Figure 3A).
A complete homozygous CFHR1 deficiency was found in
5.4% of healthy controls, which is in agreement with pre-
vious reports [18,22].
A frequency of CFHR1 deficiency, when analyzing all
patient groups used in this study (CFHR1 deficient per-
sons in FH-autoantibody negative and positive groups),
was comparable with that in the aHUS cohort (Figure 3B).
However, when analyzing the FH-autoantibody positive
patients separately we observed that 12.5 to 83.3% of
patients with LA+, SLE, RA and aHUS characterized
by FH-autoantibodies entirely lacked CFHR1 (Table 1,
Figure 3C). The Dutch RA patients were an interesting
exception with 0% CFHR1 deficiency in the FH-autoanti-
body positive patients.
It was shown previously that 77 to 88% of aHUS patients
with FH-autoantibodies were deficient for CFHR1 and
CFHR3 proteins [22]. In this study, we found that 15.2%
(7/46) of the patients with LA+, SLE and RA positive for
FH-autoantibodies had homozygous deficiency of CFHR1
compared with 25.0% (3/12) of FH-autoantibodies positive
aHUS patients. There was no difference between frequen-
cies of the deficiency of CFHR1 in patients with rheumatic
diseases negative for FH-autoantibodies (3.8%; 15/392)
compared with FH-autoantibody negative aHUS patients
(4.4%; 4/91) (Table 1). We found that there was a powerful
association between FH-autoantibody positivity and
CFHR1 deficiency in LA+. Odds ratio measured as an
increased risk for FH-autoantibody positivity depended on
CFHR1 deficiency, estimated using Fisher’s exact test was
OR = 285 (95% CI 15.4 to 5,280, P < 0.0001) for LA+ and
OR = 6.5 (95% CI 1.25 to 33.05, P = 0.04) for aHUS cohort
(Table 1). Thus, it appears that generation of FH-autoanti-
bodies is specifically associated with deficiency of CFHR1
irrespectively of which disease group is analyzed.
Discussion
A pathologic association between FH autoantibodies and
DEAP-HUS has been reported in several cohorts but the
prevalence of these antibodies has not been assessed in
other diseases. Due to involvement of complement in SLE,
RA and LA+/APS and a frequent presence of various auto-
antibodies in these diseases, we have performed a pilot
study evaluating frequency of FH autoantibodies in these
patient groups. Furthermore, we assessed prevalence of
autoantibodies directed against two other soluble comple-
ment inhibitors C4BP and FI. We found no association of
C4BP or FI autoantibodies and RA, SLE or LA+. To the
contrary, significant increase in frequency of FH-autoanti-
bodies compared to matched controls was found not only
as previously reported in aHUS but also in RA and LA+.
The analytical specificity for these three autoantibody
assays was evaluated by inhibition experiment using
excess antigen. Addition of excess purified FH, FI or
C4BP to several samples with high autoantibody titers
diminished the signal (not shown) indicating specificity
of the autoantibodies and demonstrating that the bind-
ing of these autoantibodies is not restricted to plastic
absorbed protein. Furthermore, RA patient antibodies
eluted from a PVDF membrane fragment containing FH
transferred from SDS/PAGE gel, recognized purified FH
but not pre-albumin separated by SDS/PAGE and trans-
ferred to a PVDF membrane (not shown). Incubation of
HEK293 cell lysate spiked with FH with such specifically
eluted patient FH-autoantibodies revealed mainly the
signal corresponding to FH (150 kDa) and only very
minor signals for bands around 270 kDa and 50 to
60 kDa. Thus, we concluded that FH-autoantibodies
appear to be specific for FH and do not react with other
human proteins.
FH is the main soluble inhibitor of the alternative
complement pathway due to several mechanisms [5].
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Figure 2 Binding of autoantibodies to FH fragments. Molar equivalent concentrations of the FH fragments (corresponding to CCPs 8 to 20,
CCPs 15 to 20, CCPs 19 to 20), FHL-1 (CCPs 1 to 7), FH and BSA (negative control) were coated onto ELISA plates and autoantibody binding
was determined with rabbit anti-human IgG antibodies followed by swine anti-rabbit HRP antibodies. The FH fragments used are schematically
presented in panel A. Results are shown as mean values of three independent experiments +/- SD.
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Figure 3 Complete homozygous deficiency of CFHR1. A) Plasma samples of patients and healthy controls were separated on 12% SDS-PAGE,
transferred to a PVDF membrane, and analyzed by Western blotting using a mouse monoclonal antibody against FH (C18/3) that identifies FH
(150 kDa) and the two differently glycosylated forms of CFHR1a and CFHR1b (37 and 42 kDa). Plasma samples of healthy controls are shown in
lanes 8 and 9. CFHR1 positive patients were found for aHUS (lane 2), RA (lane 4), SLE (lane 6) and LA+ (lane 7). Patients with total CFHR1
deficiency are shown for aHUS (lane 1), RA (lane 3) and SLE (lane 5). Lane 10 shows purified FH. B) Complete CFHR1 deficiency in whole patient
groups (including FH-autoantibody positive and negative patients) determined using Western blotting. C) Complete CFHR1 deficiency in FH-
autoantibody positive individuals in different disease and control groups. Numbers indicated above bars in the panel C represent number of
CFHR1 deficient patients vs. total number of patients positive for FH-autoantibodies.
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FH acts as cofactor to a serine protease FI in a degrada-
tion of C3b but it also inhibits the formation and acceler-
ates the decay of the alternative pathway C3-convertase.
The main region responsible for these activities is N-
terminal fragment composed of CCP1-4. Furthermore,
C-terminal CCPs 19 to 20 are crucial for the attachment
of FH to cellular surfaces in order to provide protection.
The mechanism by which FH autoantibodies contribute
to aHUS is still under investigation but several interesting
observations have been made. In most cases reported so
far, FH autoantibodies were directed against CCP19 to 20
of FH and did not inhibit complement inhibitory activity
of FH in the fluid phase but rather blocked binding of FH
to C3bBb convertase [16] and to cell surfaces [17]. The
C-terminus of FH is also the region in which most of the
aHUS-associated mutations are located. It has been sug-
gested that under conditions of enhanced complement
activation, a lower local concentration of FH at the cell
surface may lead to cell damage. In case of aHUS, the
main targeted tissue may be endothelium. In rheumatoid
arthritis, joint inflammation causes exudation of plasma
proteins including complement factors and inhibitors
into synovial fluid. There is strong evidence of ongoing
activation of complement in synovial fluid [9], stimulated
among others by molecules released during inflammation
from the cartilage, such as fibromodulin [35] and carti-
lage-oligomeric matrix protein [36]. FH has been shown
to attenuate complement activation initiated by these
molecules [37] and autoantibodies against FH, which we
now observed in RA patients, also bind to and function-
ally impair the N-terminus of the protein, which may
result in enhanced complement activation, ensuing
inflammation and tissue damage in joints.
We found that RA patients from two independent
cohorts have significantly increased FH autoantibody fre-
quency compared to controls. We did not find any positive
correlation between FH-autoantibody positivity and type
of treatment and other analytical data in the Swedish RA
cohort. Analysis of the Dutch RA patients did not reveal
any significant differences between the FH-autoantibodies
positive- and negative patients, regarding sex, age, autoan-
tibody status, inflammation or smoking. However, the low
number of FH-autoantibody-positive individuals highly
limits the power to reliably find such differences. Further-
more, the presence of FH-autoantibodies in several chosen
RA patients varied during disease course but it was not
associated with infections. A larger study is required to
find out if FH-autoantibodies are associated with disease
flares or severity of RA.
When analyzing samples from SLE patients, FH-auto-
antibodies could only be detected at the time point with
higher disease activity but no significant correlation
between FH-autoantibody titers and disease activity
(SLEDAI), or with any particular SLE ACR criteria were
found. This may be due to the low power to detect differ-
ences with only a few FH-autoantibody positive patients
and a low overall number of patients in this exploratory
study. Interestingly, in DEAP-HUS FH autoantibodies
were clearly lower at remission than at disease onset [32].
Potential association of FH autoantibodies with nephritis
would be of particular interest to study further due to
recently reported genetic association with FH poly-
morphisms and SLE [38], as well as association with non-
synonymous mutations in FH and CD46 with faster
onset of nephritis in SLE patients [39].
So far little information on prevalence of mutations or
polymorphisms in complement inhibitors, such as FH,
has been published for RA or APS. A recent study found
no association between common FH polymorphisms pre-
disposing to age-related macular degeneration and RA
[40]. However, our current data together with previously
published observations suggest that generation of FH-
autoantibodies is specifically associated with deficiency of
CFHR1 in many different disease groups. So far there is
no clear explanation for the association between these
two phenotypes. It has been suggested that autoantibo-
dies generated in the context of a CFHR1 deficiency are
targeted to a region of the FH molecule that is critical for
the development of aHUS, that is, CCP19 to 20, and
somehow is related to structural and functional similarity
between CFHR1 and FH [41]. However, this is not the
case for the RA patients in the current study who carry
FH-autoantibodies against many different regions of FH.
To what extent this is the effect of intra-molecular epi-
tope spreading or de-novo recognition of epitopes outside
CCP19 to 20 remains unknown. However, our results
suggest that FH-autoantibodies found in RA, SLE and LA
+ patients are polyclonal in nature since they interact
with several different regions of FH. Another conclusion
from these data could be that the combination of a dele-
tion of CFHR1 and autoantibodies against FH is a risk
factor for APS, or at least positivity for the lupus anticoa-
gulants’ test. The number of patients analyzed in this
study was limited to support such strong conclusions and
future replication studies in well-defined thrombosis and
APS patients will have to be performed to support this
observation.
Conclusions
Our study is the first to show that FH-autoantibodies can
be observed in disorders other than aHUS, such as in
patients suffering from rheumatic diseases. It has been
shown that, in DEAP-HUS, FH-autoantibodies block the
C-terminal recognition domain of FH [17], which results
in less binding of FH to cell surfaces leading to reduced
complement inhibition at these surfaces. This process is
thought to play an important role in the glomeruli of
patients suffering from DEAP-HUS during the episode of
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active disease and it is plausible that a similar process will
also impact on tissue damage during episodes of active
disease in patients suffering from these rheumatic condi-
tions. The epitope mapping experiments suggest that the
FH-autoantibodies observed in rheumatic diseases may
bind to several epitopes scattered over FH. Antibodies
against the N-terminus of FH may impair its ability to
inhibit complement both on surfaces and in body fluids
leading to a more generalized inflammation observed in
rheumatic conditions in comparison to aHUS.
Abbreviations
aHUS: atypical hemolytic uremic syndrome; APS: anti-phospholipid
syndrome; C4BP: C4b-binding protein; CCP: complement control protein;
CFHR1/CFHR3: complement FH-related proteins 1 and 3; DEAP-HUS: the
Deficiency of CFHR plasma proteins and Autoantibody Positive form of HUS;
dRVVT: dilute Russels Viper Venom; ELISA: ELISA, enzyme-linked
immunosorbent assay; FH: factor H; FI: factor I; HRP: horseradish peroxidase;
LA: lupus anticoagulants; MLPA: Mutiplex Ligation-dependent Probe
Amplification; OPD: o-phenylenediamine; PVDF: polyvinylidene difluoride; RA:
rheumatoid arthritis; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease
Activity Index.
Acknowledgements
We greatly appreciate the inspiring collaborative contribution of the late
Dr. Andrej Tarkowski and we thank the patients for their generous
participation in this study.
This work was supported by the Swedish Research Council (K2009-68X-
14928-06-3), Foundations of Söderberg, Österlund, Kock, King Gustav V’s 80th
Anniversary, Swedish Rheumatism Association, Knut and Alice Wallenberg,
Inga-Britt and Arne Lundberg as well as grants for clinical research from the
Foundation of the National Board of Health and Welfare and the Skåne
University Hospital (all to AB). LAT was financially supported by a Zon-MW
VIDI grant and by the EU-funded projects Masterswitch and IMI JU funded
project BeTheCure (contract no 115142-2). PFZ was supported by the
Deutsche Forschungsgemeinschaft (DFG).
Author details
1Department of Laboratory Medicine, Section of Medical Protein Chemistry,
Lund University, Inga Marie Nilsson street 53, 205 02 Malmö, Sweden.
2Department of Infection Biology, Leibniz Institute for Natural Product
Research and Infection Biology, Beutenbergstrasse 11a, 07745 Jena, Germany.
3Department of Rheumatology and Inflammation Research, University of
Gothenburg, Guldhedsgatan 10A, 413 46 Gothenburg, Sweden. 4Department
of Clinical Sciences Lund, Section of Rheumatology, Lund University,
Kioskgatan 3, 221 85 Lund, Sweden. 5Department of Rheumatology, Leiden
University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Authors’ contributions
AFZ and SCN performed the research. AFZ, MB, GS, SCN, TS, LAT and AMB
analyzed the results. PFZ, MB, GS, AJ, AH, TS and LAT provided patient data.
PFZ contributed vital reagents. AFZ, AMB and LAT designed the study and
wrote the paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2011 Revised: 23 July 2012
Accepted: 15 August 2012 Published: 15 August 2012
References
1. Walport MJ: Complement. First of two parts. N Engl J Med 2001,
344:1058-1066.
2. Trouw LA, Blom AM, Gasque P: Role of complement and complement
regulators in the removal of apoptotic cells. Mol Immunol 2008,
45:1199-1207.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key
system for immune surveillance and homeostasis. Nat Immunol 2010,
11:785-797.
4. Blom AM, Villoutreix BO, Dahlbäck B: Complement inhibitor C4b-binding
protein - friend or foe in the innate immune system? Mol Immunol 2004,
40:1333-1346.
5. Ferreira VP, Pangburn MK, Cortes C: Complement control protein factor H:
the good, the bad, and the inadequate. Mol Immunol 2010, 47:2187-2197.
6. Gigli I, Fujita T, Nussenzweig V: Modulation of the classical pathway C3
convertase by plasma protein C4b binding and C3b inactivator. Proc Natl
Acad Sci USA 1979, 76:6596-6600.
7. Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM: Complement
factor I in health and disease. Mol Immunol 2011, 48:1611-1620.
8. Sjöberg A, Trouw LA, Blom AM: Complement activation and inhibition - a
delicate balance. Trends Immunol 2008, 30:83-90.
9. Okroj M, Heinegård D, Holmdahl R, Blom AM: Rheumatoid arthritis and
the complement system. Ann Med 2007, 2:1-14.
10. Petry F: Molecular basis of hereditary C1q deficiency. Immunobiology
1998, 199:286-294.
11. Sturfelt G, Sjoholm AG: Complement components, complement
activation, and acute phase response in systemic lupus erythematosus.
Int Arch Allergy Appl Immunol 1984, 75:75-83.
12. Walport MJ: Complement and systemic lupus erythematosus. Arthritis Res
2002, 4(Suppl 3):S279-293.
13. Cavazzana I, Manuela N, Irene C, Barbara A, Sara S, Orietta BM, Angela T,
Francesco T, Luigi MP: Complement activation in anti-phospholipid
syndrome: a clue for an inflammatory process? J Autoimmun 2007,
28:160-164.
14. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-
Fridman C, Fremeaux-Bacchi V: Alternative complement pathway
assessment in patients with atypical HUS. J Immunol Methods 2011,
365:8-26.
15. Trouw LA, Roos A, Daha MR: Autoantibodies to complement components.
Mol Immunol 2001, 38:199-206.
16. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H,
Weiss L, Fridman WH, Fremeaux-Bacchi V: Anti-factor H autoantibodies
associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol
2005, 16:555-563.
17. Jozsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C,
Zipfel PF: Anti factor H autoantibodies block C-terminal recognition
function of factor H in hemolytic uremic syndrome. Blood 2007,
110:1516-1518.
18. Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C:
Factor H autoantibodies in atypical hemolytic uremic syndrome
correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
19. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP,
Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH,
Marchbank KJ: Association of factor H autoantibodies with deletions of
CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in
patients with atypical hemolytic uremic syndrome. Blood 2010,
115:379-387.
20. Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M,
Zipfel PF, Jozsi M: Functional analyses indicate a pathogenic role of
factor H autoantibodies in atypical haemolytic uraemic syndrome.
Nephrol Dial Transplant 2010, 25:136-144.
21. Zipfel PF, Skerka C: Complement factor H and related proteins: an
expanding family of complement-regulatory proteins? Immunol Today
1994, 15:121-126.
22. Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B,
Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH,
Skerka C: Deletion of complement factor H-related genes CFHR1 and
CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS
Genet 2007, 3:e41.
23. Zipfel PF, Mache C, Muller D, Licht C, Wigger M, Skerka C: DEAP-HUS:
deficiency of CFHR plasma proteins and autoantibody-positive form of
hemolytic uremic syndrome. Pediatr Nephrol 2010, 25:2009-2019.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,
Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
Zadura et al. Arthritis Research & Therapy 2012, 14:R185
http://arthritis-research.com/content/14/4/R185
Page 10 of 11
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG,
Talal N, Winchester RJ: The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of
the SLEDAI. A disease activity index for lupus patients. The Committee
on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
27. Thiagarajan P, Pengo V, Shapiro SS: The use of the dilute Russell viper
venom time for the diagnosis of lupus anticoagulants. Blood 1986,
68:869-874.
28. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R,
Derksen RH, PG DEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A,
Vlachoyiannopoulos PG, Krilis SA: International consensus statement on
an update of the classification criteria for definite antiphospholipid
syndrome (APS). J Thromb Haemost 2006, 4:295-306.
29. Blom AM, Kask L, Dahlbäck B: CCP1-4 of the C4b-binding protein a-chain
are required for Factor I mediated cleavage of C3b. Mol Immunol 2003,
39:547-556.
30. Blom AM, Kask L, Dahlbäck B: Structural requirements for the
complement regulatory activities of C4BP. J Biol Chem 2001,
276:27136-27144.
31. Nilsson SC, Trouw LA, Renault N, Miteva MA, Genel F, Zelazko M,
Marquart H, Muller K, Sjoholm AG, Truedsson L, Villoutreix BO, Blom AM:
Genetic, molecular and functional analyses of complement factor I
deficiency. Eur J Immunol 2009, 39:310-323.
32. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL,
Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C,
Fridman WH, Fremeaux-Bacchi V: Clinical features of anti-factor H
autoantibody-associated hemolytic uremic syndrome. JASN 2010,
21:2180-2187.
33. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F,
Fremeaux-Bacchi V, Trouw LA, Blom AM: A mutation in factor I that is
associated with atypical hemolytic uremic syndrome does not affect the
function of factor I in complement regulation. Mol Immunol 2007,
44:1845-1854.
34. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C,
Fridman WH, Fremeaux-Bacchi V: The high frequency of complement
factor H related CFHR1 gene deletion is restricted to specific subgroups
of patients with atypical haemolytic uraemic syndrome. J Med Genet
2009, 46:447-450.
35. Sjoberg A, Önnerfjord P, Morgelin M, Heinegård D, Blom AM: The
extracellular matrix and inflammation: fibromodulin activates the
classical pathway of complement by directly binding C1q. J Biol Chem
2005, 280:32301-32308.
36. Happonen KE, Saxne T, Aspberg A, Morgelin M, Heinegard D, Blom AM:
Regulation of complement by COMP allows for a novel molecular
diagnostic principle in rheumatoid arthritis. Arthritis Rheum 2010,
62:3574-3583.
37. Sjöberg A, Manderson GA, Mörgelin M, Day AJ, Heinegård D, Blom AM:
Short leucine-rich glycoproteins of the extracellular matrix display
diverse patterns of complement interaction and activation. Mol Immunol
2008, 46:830-839.
38. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, Kaufman KM,
Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A,
Glenn SB, Alarcon-Riquelme ME, Pons-Estel BA, Harley JB, Bae SC, Bang SY,
Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP,
Edberg JC, Brown EE, Alarcon GS, Petri MA, et al: Association of genetic
variants in complement factor h and factor h-related genes with
systemic lupus erythematosus susceptibility. PLoS Genet 2011, 7:e1002079.
39. Jonsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG,
Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Ronnblom L, Nordmark G,
Sturfelt G, Blom AM: Mutations in genes encoding complement inhibitors
CD46 and CFH affect the age at nephritis onset in patients with
systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R206.
40. Trouw LA, Bohringer S, Daha NA, Stahl EA, Raychaudhuri S, Kurreeman FA,
Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, Huizinga TW, Toes RE: The
major risk alleles of age-related macular degeneration (AMD) in CFH do
not play a major role in rheumatoid arthritis (RA). Clin Exp Immunol 2011,
166:333-337.
41. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de
Cordoba SR, Sanchez-Corral P: Characterization of complement factor
H-related (CFHR) proteins in plasma reveals novel genetic variations of
CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009,
114:4261-4271.
doi:10.1186/ar4016
Cite this article as: Zadura et al.: Factor H autoantibodies and deletion
of Complement Factor H-Related protein-1 in rheumatic diseases in
comparison to atypical hemolytic uremic syndrome. Arthritis Research &
Therapy 2012 14:R185.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zadura et al. Arthritis Research & Therapy 2012, 14:R185
http://arthritis-research.com/content/14/4/R185
Page 11 of 11
